2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
6
Ovarian Neoplasms
4
Neoplasms
3
Endometrial Neoplasms
3
Pancreatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Bulbo-Spinal Atrophy, X-Linked
1
Biliary Tract Neoplasms
1
Advanced Breast Cancer
1
Adenocarcinoma of Lung
1
Interventions
bicalutamide
5
enzalutamide
4
exemestane
2
darolutamide
2
abiraterone
2
pembrolizumab
1
ostarine
1
nilutamide
1
cabazitaxel
1
apalutamide
1
abemaciclib
1
Vorinostat
1
Triptorelin Pamoate
1
Tamoxifen
1
Prophylactic Mastectomy
1
Prednisolone
1
Panobinostat
1
Mifepristone
1
Letrozole
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Goserelin
1
Doxorubicin
1
Docetaxel
1
Dasatinib
1
Cisplatin
1
CP protocol
1
Aromatase Inhibitors
1
Antiemetics
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bulbo-Spinal Atrophy, X-Linked
×
AZD5305
×
Clear all
NCT07336446
2026-05-01
ANDROMEDA
AstraZeneca
Phase 1/2
Recruiting
300 enrolled